MEDIORGPharmaceuticals
MEDICAMEN ORGANICS — Profit & Loss Statement
₹21.10
+2.42%
MEDICAMEN ORGANICS Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.03 Cr | 0.23 Cr | 0.06 Cr | -0.14 Cr |
| Tax Rate For Calcs | 0.29 | 0.29 | 0.30 | 0.39 |
| Normalized EBITDA | 4.83 Cr | 1.84 Cr | 1.18 Cr | 1.97 Cr |
| Total Unusual Items | -0.10 Cr | 0.80 Cr | 0.19 Cr | -0.35 Cr |
| Total Unusual Items Excluding Goodwill | -0.10 Cr | 0.80 Cr | 0.19 Cr | -0.35 Cr |
| Net Income From Continuing Operation Net Minority Interest | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Reconciled Depreciation | 0.72 Cr | 0.71 Cr | 0.68 Cr | 0.68 Cr |
| Reconciled Cost Of Revenue | 15.80 Cr | 15.80 Cr | 15.66 Cr | 18.76 Cr |
| EBITDA | 4.73 Cr | 2.64 Cr | 1.37 Cr | 1.61 Cr |
| EBIT | 4.01 Cr | 1.93 Cr | 0.69 Cr | 0.94 Cr |
| Net Interest Income | -0.63 Cr | -0.60 Cr | -0.45 Cr | -0.43 Cr |
| Interest Expense | 0.62 Cr | 0.57 Cr | 0.44 Cr | 0.45 Cr |
| Interest Income | 0.01 Cr | 81000.00 | 0.02 Cr | 0.01 Cr |
| Normalized Income | 2.48 Cr | 0.40 Cr | -0.03 Cr | 0.51 Cr |
| Net Income From Continuing And Discontinued Operation | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Total Expenses | 21.15 Cr | 20.98 Cr | 20.46 Cr | 23.74 Cr |
| Rent Expense Supplemental | 0.04 Cr | 0.04 Cr | 0.03 Cr | 0.02 Cr |
| Diluted NI Availto Com Stockholders | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Net Income Common Stockholders | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Net Income Including Noncontrolling Interests | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Net Income Continuous Operations | 2.40 Cr | 0.97 Cr | 0.10 Cr | 0.30 Cr |
| Tax Provision | 0.98 Cr | 0.39 Cr | 0.15 Cr | 0.19 Cr |
| Pretax Income | 3.39 Cr | 1.36 Cr | 0.26 Cr | 0.49 Cr |
| Other Non Operating Income Expenses | 28000.00 | 66000.00 | — | — |
| Special Income Charges | -0.10 Cr | 0.80 Cr | 0.19 Cr | -0.35 Cr |
| Write Off | 0.10 Cr | -0.80 Cr | -0.19 Cr | 0.35 Cr |
| Net Non Operating Interest Income Expense | -0.63 Cr | -0.60 Cr | -0.45 Cr | -0.43 Cr |
| Total Other Finance Cost | 0.02 Cr | 0.05 Cr | 0.04 Cr | — |
| Interest Expense Non Operating | 0.62 Cr | 0.57 Cr | 0.44 Cr | 0.45 Cr |
| Interest Income Non Operating | 0.01 Cr | 81000.00 | 0.02 Cr | 0.01 Cr |
| Operating Income | 4.12 Cr | 1.17 Cr | 0.52 Cr | 1.31 Cr |
| Operating Expense | 5.35 Cr | 5.18 Cr | 4.80 Cr | 4.98 Cr |
| Other Operating Expenses | 24000.00 | 39000.00 | 49000.00 | 0.01 Cr |
| Depreciation And Amortization In Income Statement | 0.72 Cr | 0.71 Cr | 0.68 Cr | 0.68 Cr |
| Depreciation Income Statement | 0.72 Cr | 0.71 Cr | 0.68 Cr | 0.68 Cr |
| Selling General And Administration | 1.24 Cr | 1.26 Cr | 1.21 Cr | 1.47 Cr |
| Selling And Marketing Expense | 0.19 Cr | 0.39 Cr | 0.41 Cr | 0.56 Cr |
| General And Administrative Expense | 1.04 Cr | 0.86 Cr | 0.80 Cr | 0.91 Cr |
| Rent And Landing Fees | 0.04 Cr | 0.04 Cr | 0.03 Cr | 0.02 Cr |
| Gross Profit | 9.47 Cr | 6.35 Cr | 5.32 Cr | 6.29 Cr |
| Cost Of Revenue | 15.80 Cr | 15.80 Cr | 15.66 Cr | 18.76 Cr |
| Total Revenue | 25.27 Cr | 22.15 Cr | 20.98 Cr | 25.05 Cr |
| Operating Revenue | 25.27 Cr | 22.15 Cr | 20.98 Cr | 25.05 Cr |
| Diluted Average Shares | — | 1.17 Cr | 1.17 Cr | 1.17 Cr |
| Basic Average Shares | — | 1.17 Cr | 1.17 Cr | 1.17 Cr |
| Diluted EPS | — | 0.83 | 0.09 | 0.25 |
| Basic EPS | — | 0.83 | 0.09 | 0.25 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on MEDICAMEN ORGANICS
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.